ObjectiveTo observe the changes of serum homocysteine acid ( Hcy),interleukin-6 (IL-6) and high sensitive C-reactive protein (hs-CRP)and elucidate the clinical significance in patients with acute stroke. MethodsA total of 126 acute stroke patients were enrolled in the investigation. Based on the MESS,patients were divided into different groups according the severity and prognosis, and 108 physically healthy subjects were selected as controls. The concentration of serum Hcy, IL-6, and hs-CRP were determined in all cases after being attacked at day 3,day 14 and day 28 respectively. Results①The levels of Hcy, IL-6, hs-CRP in patients with acute stroke were significantly higher than controls ( (58.24 ±9.86) μmol/L vs. ( 17.12 ±4.23) μ mol/L, (59.64 ±13.82) ng/L vs. (18.46 ±4.62) ng/L,(19.78 ±6.12) mg/L vs. (2.28 ±0.82) mg/L,all P＜0. 01 ). ②The levels of Hcy,IL-6, hs-CRP in patients with mild, moderate and severe acute stroke were significantly higher than controls (P ＜ 0.01 ) at 3 day after the onset; and the Hcy, IL-6, hs-CRP were also significantly lower in mild cases with acute stroke compared with moderate and severe cases (P ＜ 0. 01 ). At day 14 ,the moderate and severe patients had significantly higher levels of Hcy, IL-6, hs-CRP than mild cases and controls (P ＜ 0.01 ). At day 28 the severe patients had significantly higher levels of Hcy, IL-6, hs-CRP than mild and moderate cases and controls (P ＜ 0.01 ) ③At day 28, the levels of Hcy, IL-6, hs-CRP in basically recovered and remarkably improved cases were significantly lower than unrecovered cases [ ( 16.12 ± 4.74) μmol/L, ( 1 8.42 ± 5.02) μ mol/L vs. ( 48.69 ± 7.89)μmol/L; ( 19.52 ± 5.67 ) ng/L, ( 20. 74 ± 6. 13 ) ng/L vs. ( 51.26 ± 11.66 ) ng/L, ( 3.21 ± 1.36) mg/L,(3.24 ± 2.51 ) mg/L vs. ( 8.86 ± 1.32 ) mg/L respectively, all P ＜ 0. 01 ]. ConclusionsThe levels of serum Hcy, IL-6, hs-CRP are significant biomarkers to evaluate the severity and prognosis of acute stroke.

Objective:To prepare monoclonal antibodies specific to human papillomavirus type 6 L1 (HPV6 L1) protein, investigate the binding characteristics, cross-reactivity, and neutralization efficacy of these antibodies.Methods:Antibody genes were extracted from the spleen cells of mice immunized with HPV6 L1 protein and used to construct an ScFv phage antibody library. The library was enriched and screened using HPV6 L1 protein. Following expression of the antibody genes into murine IgG, the binding properties of the antibodies to the L1 protein and their neutralization effects on pseudoviruses were verified.Results:An ScFv antibody library targeting HPV6 L1 was successfully constructed with a capacity of 6.54×10 7. After screening with HPV6 L1, two antibody strains were obtained, named Q9 and Q11. ELISA testing revealed that Q9-IgG has a high antibody titer (about 10 6) against HPV6 L1, while cross-reactivity titers to HPV18 and 45 L1 were 10 2. Q11-IgG has an antibody titer about 4×10 4 against HPV6 L1, but not combined with the L1 proteins of other HPV types. Pseudovirus neutralization assays indicated that Q9-IgG lacked neutralizing activity, while Q11-IgG showed a neutralizing antibody titer of 10 4.5against HPV6 pseudovirus. Conclusions:Both Q9 and Q11 are monoclonal antibodies specific to HPV6 L1. However, they displayed notable differences in cross-reactivity, antigen recognition sites, and neutralization efficacy. These antibodies provide essential tools for the foundational research of HPV6, immunological diagnosis, and the development of therapeutic formulations.